ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > We need some answers

<< Previous

Bullboard Posts

Next >>

Comment by farmerjaneon Oct 22, 2021 12:01pm

134 Views

Post# 34037764

RE:RE:RE:RE:RE:We need some answers

Now why would the Boston group quickly do a another PP. Last month when they presented at a conference page 3 Summary " Recently completed 20.15 million financing, fully funded through 2022, to IND Filing for lead program"

Owe they snuck another corporate update yesterday October 22, 2021 three down on there homepage not at the top, wow what a bunch. No mention of above financing.

<< Previous

Bullboard Posts

Next >>

Level up your trading with BMO InvestorLine’s enhanced features